Byline: Dunstan Prial
Jan. 10--Johnson & Johnson will probably be forced to sweeten its bid for Guidant Corp. if the health-care giant hopes to stay in the running to acquire the troubled medical device maker, analysts following the situation said Monday.
"It will take a higher offer for them to remain a player," said John Putnam, an analyst with Stanford Group Co.
New Brunswick-based Johnson & Johnson, responding to a definitive $25 billion offer for Guidant from Boston Scientific Corp., has said it will not back out of the deal.
Announced Sunday, Boston Scientific's offer essentially reaffirmed its intention made last month to outbid …